Abstract

ObjectiveWe aimed to better clarify the role of germline variants of the FCG2 receptor, FCGR2A-H131R and FCGR3A-V158F, on the therapeutic efficacy of cetuximab in metastatic colorectal cancer (mCRC). A large...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Abstract B41: Different clinical outcomes of systemic chemotherapy in non-small cell lung cancer without EGFR and K-ras mutation according to smoking status.
Sook Hee Hong ... Eun Kyung Jeon
Molecular Cancer Therapeutics | VOL. 12
Sook Hee Hong, et. al.Sook Hee Hong ... Eun Kyung Jeon
01 Nov 2013
Fc gamma receptor polymorphisms and KRAS status as predictive biomarkers in patients with metastatic colorectal cancer treated with biweekly cetuximab-based salvage therapy.
R Zarate ... E Bandres
Journal of Clinical Oncology | VOL. 28
R Zarate, et. al.R Zarate ... E Bandres
20 May 2010
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients
F Loupakis ... P Bohanes
The Pharmacogenomics Journal | VOL. 14
F Loupakis, et. al.F Loupakis ... P Bohanes
11 Feb 2014
Metastatic Colorectal Cancer Treatment Patterns According to Kirsten Rat Sarcoma Viral Oncogene Homolog Genotype in U.S. Community-Based Oncology Practices
Pamela B Landsman-Blumberg ... Veena Shankaran
Clinical Colorectal Cancer | VOL. 13
Pamela B Landsman-Blumberg, et. al.Pamela B Landsman-Blumberg ... Veena Shankaran
23 Jun 2014
View more papers

More From: Gut

Paper Title
Journal
Date
Author
Metabolic reprogramming by mutant GNAS creates an actionable dependency in intraductal papillary mucinous neoplasms of the pancreas
Yuki Makino ... Fredrik Ivar Thege
Gut | VOL. -
Yuki Makino, et. al.Yuki Makino ... Fredrik Ivar Thege
13 Sep 2024
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989
Lung Yi Mak ... Man-Fung Yuen
Gut | VOL. -
Lung Yi Mak, et. al.Lung Yi Mak ... Man-Fung Yuen
12 Sep 2024
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma
Jasmin Elurbide ... Matias A Avila
Gut | VOL. -
Jasmin Elurbide, et. al.Jasmin Elurbide ... Matias A Avila
11 Sep 2024
Extending inflamed-class signature to predict immune checkpoint inhibitor-based combination therapy in hepatocellular carcinoma
Wenhua You ... Yun Chen
Gut | VOL. -
Wenhua You, et. al.Wenhua You ... Yun Chen
11 Sep 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.